Return to Publications
November 2016
RWJBarnabas HealthRutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.
Top Docs

Rutgers Cancer Institute Physicians Named Among 'Jersey Choice Top Doctors' in State

Several physicians at Rutgers Cancer Institute of New Jersey have been named as a 'Jersey Choice Top Doctor' for 2016 by New Jersey Monthly magazine. Thousands of New Jersey-based doctors were asked to give physician recommendations and more than 1,000 physicians were named to the final list following a professional review by an independent panel of doctors. Rutgers Cancer Institute physicians on this year's list are also faculty members at Rutgers Robert Wood Johnson Medical School.

Shine a Light on Lung Cancer

Shining a Light on Lung Cancer

Rutgers Cancer Institute is hosting a 'Shine a Light on Lung Cancer' event at its New Brunswick facility on Thursday, November 17. The program will feature discussion by Rutgers Cancer Institute surgical, medical and radiation oncologists on the latest in lung cancer treatment, research and prevention - including information on lung cancer screening. The program, which also features dinner and giveaways,  is free, but registration is required.

Wenwei Hu, PhD

Chronic Stress Explored in Breast Cancer Development with Support from U.S. Department of Defense Grant

Rutgers Cancer Institute of New Jersey resident research member Wenwei Hu, PhD, has received a $596,250 Breakthrough Award (W81XWH-16-1-0358) from the U.S. Department of Defense through its Breast Cancer Research Program to study the role of chronic stress in breast cancer development. Dr. Hu, who is an associate professor of radiation oncology at Rutgers Robert Wood Johnson Medical School, will explore how chronic stress impacts breast cancer risk with an aim of providing a foundation that can guide prevention strategies.

Darren Carpizo, MD, PhD

Grant Supports Examination of Drug Compound on Common Cancer Mutation

A $250,000 grant awarded to Rutgers Cancer Institute of New Jersey surgical oncologist Darren R. Carpizo, MD, PhD, will further aid the work of the physician-scientist in exploration of mechanisms behind the p53 gene, the most commonly mutated gene in human cancer. The funding from the Breast Cancer Research Foundation will help Dr. Carpizo, an associate professor of surgery at Rutgers Robert Wood Johnson Medical School, build upon his previous research in examining a drug compound that restores tumor suppressor function of p53.

Hossein Khiabanian, PhD

Understanding the Mutational Landscape of the Most Common Pediatric Cancer

Researchers from Columbia University, Rutgers University, and other institutions have identified genomic alterations in pediatric relapsed acute lymphoblastic leukemia (ALL) that cause both therapy resistance and improved clinical response to multi-agent chemotherapy treatment. Rutgers Cancer Institute of New Jersey researcher Hossein Khiabanian, PhD, an assistant professor of pathology at Rutgers Robert Wood Johnson Medical School, was involved in the work.